Indoco Remedies gets USFDA’s nod for Apixaban Tablets
14th Sep 2020

Indoco Remedies has received approval from US Food and Drug Administration (USFDA) for its ANDA for Apixaban Tablets 2.5mg & 5mg. The products are therapeutically equivalent to the Reference Listed Drug ‘Eliquis’ of Bristol-Myers Squibb (BMS). Apixaban is an anticoagulant, or blood thinner. It is used for patients with health problems caused by a blood clot. The US market size of Apixaban Tablets is $11,037 million as per IMS MAT June 2020 data. 

Indoco Remedies is engaged in the manufacturing and marketing of formulations (finished dosage forms) and active pharmaceutical ingredients (APIs) in India.